Literature DB >> 15350971

Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease.

Akihiko Nunomura1, Shigeru Chiba, Carol F Lippa, Patrick Cras, Rajesh N Kalaria, Atsushi Takeda, Kazuhiro Honda, Mark A Smith, George Perry.   

Abstract

An in situ approach was used to identify the oxidized RNA nucleoside 8-hydroxyguanosine (8OHG) in the frontal cortex of familial Alzheimer's disease (FAD) with a mutation in presenilin-1 (PS-1) or amyloid beta protein precursor (AbetaPP) gene (n = 13, age 47-81 years). Neurons with marked 8OHG immunoreaction in the cytoplasm were widely distributed in the superior/middle frontal gyrus of FAD. Relative intensity measurements of neuronal 8OHG immunoreactivity showed that there was a significant increase in FAD compared with controls (n = 15, age 59-81 years), while there was no difference in relative 8OHG between the PS-1 and the AbetaPP FAD. Interestingly, a presymptomatic case carrying a PS-1 mutation showed a considerable level of relative 8OHG, and the increased levels of neuronal 8OHG in FAD were more prominent in cases with a lower percentage area of Abeta42 burden. These results suggest that oxidative stress is an early event involved in the pathological cascade of FAD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350971     DOI: 10.1016/j.nbd.2004.06.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  55 in total

Review 1.  Oxidative damage to RNA in aging and neurodegenerative disorders.

Authors:  Akihiko Nunomura; Paula I Moreira; Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

Review 2.  Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Hyoung-gon Lee; George Perry; Xiongwei Zhu; Rudy J Castellani; Mark A Smith
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 3.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

Review 4.  Current perspectives on the clinical implications of oxidative RNA damage in aging research: challenges and opportunities.

Authors:  Zhijie Xu; Jinzhou Huang; Ming Gao; Guijie Guo; Shuangshuang Zeng; Xi Chen; Xiang Wang; Zhicheng Gong; Yuanliang Yan
Journal:  Geroscience       Date:  2020-06-11       Impact factor: 7.713

5.  The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons.

Authors:  Akihiko Nunomura; Toshio Tamaoki; Nobutaka Motohashi; Masao Nakamura; Daniel W McKeel; Massimo Tabaton; Hyoung-Gon Lee; Mark A Smith; George Perry; Xiongwei Zhu
Journal:  J Neuropathol Exp Neurol       Date:  2012-03       Impact factor: 3.685

6.  The fallacy of amyloid and cognition in Alzheimer's disease.

Authors:  Hyoung-gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 7.  Indices of metabolic dysfunction and oxidative stress.

Authors:  Gemma Casadesus; Paula I Moreira; Akihiko Nunomura; Sandra L Siedlak; William Bligh-Glover; Elizabeth Balraj; Grace Petot; Mark A Smith; George Perry
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

8.  Up-regulation of the mitochondrial malate dehydrogenase by oxidative stress is mediated by miR-743a.

Authors:  Qingli Shi; Gary E Gibson
Journal:  J Neurochem       Date:  2011-06-24       Impact factor: 5.372

Review 9.  Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.

Authors:  Hans Lassmann
Journal:  J Neural Transm (Vienna)       Date:  2011-03-05       Impact factor: 3.575

Review 10.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.